VTAMA (tapinarof)
VTAMA is a topical cream that treats plaque psoriasis in adults. It also helps patients with atopic dermatitis, including both adults and children as young as two years old. This medication is used to manage these skin conditions through its action as an aryl hydrocarbon receptor agonist.
How VTAMA Works
This medication works by acting as an aryl hydrocarbon receptor (AhR) agonist. While the specific mechanisms by which the cream exerts its therapeutic actions are currently unknown, it targets this receptor to help improve the skin.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2022-05-23
- Patent Cliff
- 2039
- Routes
- TOPICAL
- Dosage Forms
- CREAM
VTAMA Approval History
What VTAMA Treats
2 indicationsVTAMA is approved for 2 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Plaque Psoriasis
- Atopic Dermatitis
VTAMA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in VTAMA's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications VTAMA treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to VTAMA
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
6 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06561321 | 21197 | Ph 2 | recruiting | Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma |
| NCT07352566 | 25-43621 | Ph 4 | not yet recruiting | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
| NCT05981118 | IRB00099131 | Ph 2, Ph 3 | enrolling by invitation | Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) |
| NCT03983980 results posted | DMVT-505-3002 | Ph 3 | completed | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) |
| NCT03956355 results posted | DMVT-505-3001 | Ph 3 | completed | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) |
| NCT06103695 | PTC10 | Ph 4 | completed | Vtama in Psoriasis Patients Being Treated With Biologics. |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VTAMA FDA Label Details
Indications & Usage
FDA Label (PDF)VTAMA is indicated for the treatment of Plaque Psoriasis; Atopic Dermatitis.
VTAMA Patents & Exclusivity
Patents (12 active)
Exclusivity
Pro Intelligence Preview
Deep insights for VTAMA
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2039
- • 14 active patents
Trial Analysis
- • 7 total trials
- • Stage: Expansion
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment